MANGROVE PARTNERS IM, LLC - CATALYST PHARMACEUTICALS INC ownership

CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 103 filers reported holding CATALYST PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 1.68 and the average weighting 0.1%.

Quarter-by-quarter ownership
MANGROVE PARTNERS IM, LLC ownership history of CATALYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2020$9,005,000
-37.7%
3,031,965
-3.1%
1.14%
-67.8%
Q2 2020$14,462,000
-13.8%
3,130,195
-28.1%
3.53%
+52.6%
Q1 2020$16,768,000
+188.8%
4,355,416
+181.3%
2.31%
+172.1%
Q4 2019$5,806,000
-56.4%
1,548,316
-38.3%
0.85%
-47.3%
Q3 2019$13,322,000
-9.6%
2,508,838
-34.6%
1.61%
-3.1%
Q2 2019$14,735,000
-16.4%
3,837,181
+11.0%
1.67%
-29.3%
Q1 2019$17,631,000
+287.8%
3,457,041
+46.0%
2.36%
+289.1%
Q4 2018$4,547,000
-28.3%
2,368,330
+41.1%
0.61%
+51.5%
Q3 2018$6,343,000
+21.2%
1,677,9440.0%0.40%
+18.7%
Q2 2018$5,235,000
+45.2%
1,677,944
+11.2%
0.34%
+43.4%
Q1 2018$3,605,000
-0.3%
1,508,309
+63.1%
0.24%
-51.8%
Q4 2017$3,615,000924,6480.49%
Other shareholders
CATALYST PHARMACEUTICALS INC shareholders Q2 2019
NameSharesValueWeighting ↓
TANAKA CAPITAL MANAGEMENT INC 148,281$1,902,0005.68%
GABLES CAPITAL MANAGEMENT INC. 433,814$5,566,0004.46%
Quantedge Capital Pte Ltd 503,700$6,462,0001.99%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 4,896,000$62,816,0001.25%
Lanham O'Dell & Company, Inc. 20,145$258,0000.92%
Capital Impact Advisors, LLC 59,301$907,0000.90%
SummerHaven Investment Management, LLC 98,840$1,268,0000.88%
Yorktown Management & Research Co Inc 50,000$642,0000.83%
GLOBEFLEX CAPITAL L P 304,293$3,904,0000.67%
AFFINITY INVESTMENT ADVISORS, LLC 90,864$1,166,0000.60%
View complete list of CATALYST PHARMACEUTICALS INC shareholders